Addressing financial and logistical challenges associated with pegfilgrastim : updating electronic ordering methodology and converting to the Neulasta® on-body injector
No Thumbnail Available
Sponsors
Date
Journal Title
Format
poster
Subject
Abstract
"Neutropenia is a significant dose-limiting toxicity associated with numerous chemotherapy agents and can potentially result in significant infectious complications, prolonged hospitalizations, and death. Granulocyte colony-stimulating growth factors such as pegfilgrastim (Neulasta®) are routinely given following the administration of chemotherapy in order to reduce the severity and duration of neutropenia and to minimize the risk of severe adverse effects related to various cancer therapies. Although a vital clinical tool, pegfilgrastim is associated with several important logistical challenges owing to its high cost and requirement for administration on the day following the completion of chemotherapy. A multidisciplinary group convened in response to routine occurrence of billing errors for pegfilgrastim claims and progressive difficulty of arranging growth factor therapy."
Table of Contents
DOI
PubMed ID
Degree
Thesis Department
Rights
All rights reserved to the author(s) of the poster.